比较热消融单药治疗与经动脉化疗栓塞联合治疗肝细胞癌的长期生存获益:一项倾向性评分匹配研究
该研究纳入2015年1月1日至2021年2月28日连续432例BCLC 0-B期肝细胞癌患者,均接受超声引导经皮热消融(射频消融340例、微波消融92例)。经倾向性评分匹配后146例(单药组73例、联合组73例)分析显示,两组局部肿瘤进展、无病生存和总生存率差异均无统计学意义。作者认为对于BCLC 0-B期患者,热消融前联合TACE可能与长期生存获益无关。
要点
- 匹配后单药组与联合组局部肿瘤进展率无显著差异(P=0.960)。
- 匹配后两组无病生存(P=0.070)和总生存(P=0.680)均无显著差异。
- 超声回声、最小消融边缘及高肿瘤负荷评分与局部肿瘤进展相关。
核心结论
- BCLC 0-B期肝细胞癌患者中,热消融单药与TACE联合热消融在局部肿瘤进展、无病生存和总生存率上差异均无统计学意义(P分别为0.960、0.070、0.680)。
研究设计与样本
- 单中心连续性队列研究,2015年1月1日至2021年2月28日纳入432例BCLC 0-B期肝细胞癌患者(男357例、女75例,年龄20-87岁)。
- 所有患者接受超声引导经皮热消融,包括射频消融340例和微波消融92例。
- 采用倾向性评分匹配后最终匹配队列146例,热消融单药组73例、热消融联合TACE组73例。
- 局部肿瘤进展采用逻辑回归模型分析,无病生存和总生存采用Cox比例风险模型分析。
诊断标准与关键数值
- 匹配后两组累积局部肿瘤进展率差异无统计学意义(P=0.960)。
- 匹配后两组无病生存率差异无统计学意义(P=0.070)。
- 匹配后两组总生存率差异无统计学意义(P=0.680)。
- 多因素分析显示超声回声、最小消融边缘和高风险肿瘤负荷评分与局部肿瘤进展相关。
- 多因素分析显示热消融类型、Child-Turcotte-Pugh分级、消融时间和淋巴细胞-单核细胞比值是总生存的独立预后因素。
临床应用与阅片要点
- 对于BCLC 0-B期肝细胞癌,热消融前联合TACE可能与长期生存获益无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the long-term survival benefits of hepatocellular carcinoma (HCC) in thermal ablation (TA) monotherapy and TA combined with transarterial chemoembolization (TACE) using propensity score matching (PSM).
MATERIALS AND METHODS: Between 1 January 2015 and 28 February 2021, 432 consecutive patients (357 men, 75 women; age range, 20-87 years) with HCC (Barcelona Clinic Liver Cancer stage 0-B) underwent ultrasonography-guided percutaneous TA, which included radiofrequency ablation (n = 340) and microwave ablation (n = 92). The association between combined treatment of TACE prior to TA versus TA monotherapy and survival prognosis was evaluated, including (a) local tumor progression (LTP) by using a logistic regression model, and (b) disease-free survival (DFS) and (c) overall survival (OS) by using a Cox proportional hazards model according to propensity score matched data.
RESULTS: After PSM, the final matched cohort consisted of 146 patients, with 73 receiving TA monotherapy and 73 receiving TA combined with TACE. The cumulative LTP rates did not show a significant difference between the two groups (P = 0.960). Neither the DFS nor OS rate was significantly different between the two groups (P = 0.070 and P = 0.680, respectively). The multivariate analysis identified two significant findings. Firstly, ultrasound echo, minimal ablative margin, and high risk of tumor burden score were found to be associated with LTP. Secondly, the type of TA, Child-Turcotte-Pugh grade, ablation time, and lymphocyte-monocyte ratio were identified as independent prognostic factors for OS.
CONCLUSION: The differences in LTP, DFS, and OS rates of HCC patients were found to be statistically non-significant between TA monotherapy and TACE + TA groups. For HCC patients with BCLC stage 0-B, the combination treatment of TACE prior to TA may be not associated with long-term survival benefits relative to TA monotherapy.
引用
- Zhang K, Mu L, Ren Y, et al. Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study. Eur J Radiol. 2023. PMID: 37708678. doi:10.1016/j.ejrad.2023.111092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。